MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Tiotropium/Salmeterol Inhalation Powder in COPD

Phase 3
Terminated
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Tiotropium/Salmeterol
Drug: Placebo
First Posted Date
2008-04-29
Last Posted Date
2023-11-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
207
Registration Number
NCT00668772
Locations
🇱🇻

1184.15.37153 Boehringer Ingelheim Investigational Site, Tukums, Latvia

🇺🇸

1184.15.01071 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States

🇩🇰

1184.15.45054 Boehringer Ingelheim Investigational Site, Aalborg, Denmark

and more 61 locations

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3
Terminated
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Tiotropium/Salmeterol QD
Drug: Placebo
First Posted Date
2008-04-21
Last Posted Date
2023-08-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
220
Registration Number
NCT00662740
Locations
🇺🇸

1184.14.01006 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States

🇺🇸

1184.14.01015 Boehringer Ingelheim Investigational Site, South Bend, Indiana, United States

🇳🇱

1184.14.31001 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands

and more 69 locations

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Tiotropium/Salmeterol (T+S_PE)
First Posted Date
2008-04-21
Last Posted Date
2022-06-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
147
Registration Number
NCT00662792
Locations
🇩🇪

1184.13.1312 Boehringer Ingelheim Investigational Site, Hamburg, Germany

🇩🇪

1184.13.1305 Boehringer Ingelheim Investigational Site, Mainz, Germany

🇩🇪

1184.13.1301 Boehringer Ingelheim Investigational Site, Mannheim, Germany

and more 9 locations

Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension

Completed
Conditions
Hypertension
First Posted Date
2008-04-16
Last Posted Date
2014-06-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6901
Registration Number
NCT00659607
Locations
🇰🇷

Boehringer Ingelheim Investigational Site 14, Seoul, Korea, Republic of

🇰🇷

Boehringer Ingelheim Investigational Site 15, Seoul, Korea, Republic of

🇰🇷

Boehringer Ingelheim Investigational Site 12, Seoul, Korea, Republic of

and more 71 locations

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Completed
Conditions
Hypertension
Interventions
First Posted Date
2008-04-16
Last Posted Date
2016-08-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
21471
Registration Number
NCT00659581

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Phase 3
Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2008-04-14
Last Posted Date
2014-07-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2055
Registration Number
NCT00657150
Locations
🇺🇸

1160.64.01003 Boehringer Ingelheim Investigational Site, Missoula, Montana, United States

🇺🇸

1160.64.01002 Boehringer Ingelheim Investigational Site, Houston, Texas, United States

🇨🇦

1160.64.6011 Boehringer Ingelheim Investigational Site, Oshawa, Ontario, Canada

and more 105 locations

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Phase 3
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: placebo
First Posted Date
2008-04-10
Last Posted Date
2016-07-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
585
Registration Number
NCT00656136
Locations
🇧🇪

1200.23.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium

🇧🇪

1200.23.32005 Boehringer Ingelheim Investigational Site, Liège, Belgium

🇨🇦

1200.23.1001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada

and more 87 locations

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Phase 3
Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Placebo
First Posted Date
2008-04-08
Last Posted Date
2014-06-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
306
Registration Number
NCT00654498
Locations
🇨🇳

248.630.06 Boehringer Ingelheim Investigational Site, Beijing, China

🇨🇳

248.630.07 Boehringer Ingelheim Investigational Site, Beijing, China

🇨🇳

248.630.01 Boehringer Ingelheim Investigational Site, Shanghai, China

and more 13 locations

Japanese P III vs Voglibose and Placebo

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: BI 1356 placebo
First Posted Date
2008-04-08
Last Posted Date
2014-01-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
561
Registration Number
NCT00654381
Locations
🇯🇵

1218.23.33 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

🇯🇵

1218.23.35 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

🇯🇵

1218.23.19 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan

and more 44 locations

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Completed
Conditions
Parkinson Disease
First Posted Date
2008-04-02
Last Posted Date
2014-05-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
286
Registration Number
NCT00651183
Locations
🇦🇹

Boehringer Ingelheim Investigational Site, Wörgl, Austria

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy